NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength (Ascending) | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
68382-0918-18 | 68382-0918 | methylprednisolone | methylprednisolone | 16.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 1, 2018 | In Use | |
68382-0918-77 | 68382-0918 | methylprednisolone | methylprednisolone | 16.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 1, 2018 | In Use | |
70771-1350-01 | 70771-1350 | methylprednisolone | methylprednisolone | 16.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 1, 2018 | In Use | |
70771-1350-04 | 70771-1350 | methylprednisolone | methylprednisolone | 16.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 1, 2018 | In Use | |
70771-1350-05 | 70771-1350 | methylprednisolone | methylprednisolone | 16.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 1, 2018 | In Use | |
70771-1350-07 | 70771-1350 | methylprednisolone | methylprednisolone | 16.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 1, 2018 | In Use | |
00179-0124-70 | 00179-0124 | Methylprednisolone | Methylprednisolone | 16.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 12, 2012 | May 31, 2015 | In Use |
10631-0003-31 | 10631-0003 | isotretinoin | Absorica LD | 16.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Nov. 20, 2019 | In Use | |
68180-0688-08 | 68180-0688 | Methylprednisolone | Methylprednisolone | 16.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | March 1, 2020 | In Use | |
68001-0559-69 | 68001-0559 | Methylprednisolone | Methylprednisolone | 16.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan. 31, 2023 | In Use | |
00002-7716-01 | 00002-7716 | Necitumumab | Portrazza | 16.0 mg/mL | Immunotherapy | Monoclonal Antibody | EGFR | Intravenous | Nov. 24, 2015 | In Use | |
51672-1338-03 | 51672-1338 | Prednisolone Acetate | Flo-Pred | 16.7 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan. 17, 2008 | March 17, 2023 | In Use |
51672-1338-05 | 51672-1338 | Prednisolone Acetate | Flo-Pred | 16.7 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan. 17, 2008 | March 17, 2023 | In Use |
51672-1338-06 | 51672-1338 | Prednisolone Acetate | Flo-Pred | 16.7 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan. 17, 2008 | March 17, 2023 | In Use |
51672-1338-08 | 51672-1338 | Prednisolone Acetate | Flo-Pred | 16.7 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan. 17, 2008 | Feb. 12, 2010 | In Use |
00310-9500-01 | 00310-9500 | Capivasertib | TRUQAP | 160.0 mg/1 | Chemotherapy | AKT Inhibitor | AKT1/2/3 | Oral | Nov. 16, 2023 | In Use | |
69097-0372-47 | 69097-0372 | Docetaxel Anhydrous | Docetaxel Anhydrous | 160.0 mg/16mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug. 24, 2018 | Aug. 26, 2020 | In Use |
43598-0389-57 | 43598-0389 | Docetaxel | Docetaxel | 160.0 mg/8mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | April 22, 2019 | In Use | |
47335-0939-40 | 47335-0939 | Docetaxel | Docetaxel | 160.0 mg/8mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Nov. 26, 2020 | In Use | |
72485-0216-08 | 72485-0216 | Docetaxel | Docetaxel | 160.0 mg/8mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan. 15, 2020 | In Use | |
70121-1223-01 | 70121-1223 | Docetaxel | Docetaxel | 160.0 mg/8mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan. 19, 2018 | In Use | |
00955-1022-08 | 00955-1022 | Docetaxel | Docetaxel | 160.0 mg/8mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct. 23, 2016 | In Use | |
65597-0504-04 | 65597-0504 | QUIZARTINIB | VANFLYTA | 17.7 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | July 20, 2023 | In Use | |
65597-0504-28 | 65597-0504 | QUIZARTINIB | VANFLYTA | 17.7 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | July 20, 2023 | In Use | |
43598-0771-11 | 43598-0771 | LEVOLEUCOVORIN | LEVOLEUCOVORIN | 175.0 mg/17.5mL | Ancillary Therapy | Chemoprotective | Antidote | Intravenous | Sept. 26, 2018 | In Use | |
16714-0890-01 | 16714-0890 | LEVOLEUCOVORIN | LEVOLEUCOVORIN | 175.0 mg/17.5mL | Ancillary Therapy | Chemoprotective | Antidote | Intravenous | Sept. 26, 2018 | In Use | |
00781-3201-94 | 00781-3201 | Levoleucovorin | Levoleucovorin | 175.0 mg/17.5mL | Ancillary Therapy | Chemoprotective | Antidote | Intravenous | April 23, 2015 | April 30, 2023 | No Longer Used |
72893-0004-01 | 72893-0004 | Levoleucovorin | KHAPZORY | 175.0 mg/3.5mL | Ancillary Therapy | Chemoprotective | Antidote | Intravenous | Jan. 2, 2019 | In Use | |
68152-0112-01 | 68152-0112 | levoleucovorin | KHAPZORY | 175.0 mg/3.5mL | Ancillary Therapy | Chemoprotective | Antidote | Intravenous | Jan. 2, 2019 | In Use | |
47335-0930-21 | 47335-0930 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb. 13, 2014 | In Use | |
47335-0930-72 | 47335-0930 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb. 13, 2014 | In Use | |
47335-0930-74 | 47335-0930 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb. 13, 2014 | In Use | |
47335-0930-75 | 47335-0930 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb. 13, 2014 | In Use | |
47335-0930-80 | 47335-0930 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb. 13, 2014 | In Use | |
47335-0930-87 | 47335-0930 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb. 13, 2014 | In Use | |
55135-0132-01 | 55135-0132 | SACITUZUMAB GOVITECAN | TRODELVY | 180.0 mg/1 | Immunotherapy | Drug Antibody Conjugate | Trop-2 | Intravenous | April 23, 2020 | In Use | |
00054-0324-03 | 00054-0324 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | March 24, 2016 | March 24, 2016 | No Longer Used |
00054-0324-06 | 00054-0324 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | March 24, 2016 | March 24, 2016 | No Longer Used |
16729-0130-53 | 16729-0130 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | March 7, 2017 | In Use | |
16729-0130-54 | 16729-0130 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | March 7, 2017 | In Use | |
40051-0608-11 | 40051-0608 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug. 1, 2016 | In Use | |
40051-0608-12 | 40051-0608 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug. 1, 2016 | In Use | |
40051-0608-13 | 40051-0608 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug. 1, 2016 | In Use | |
40051-0608-51 | 40051-0608 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug. 1, 2016 | In Use | |
40051-0608-52 | 40051-0608 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug. 1, 2016 | In Use | |
40051-0608-53 | 40051-0608 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug. 1, 2016 | In Use | |
54868-5980-00 | 54868-5980 | Temozolomide | Temodar | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 26, 2009 | In Use | |
64144-0505-01 | 64144-0505 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | April 13, 2016 | In Use | |
64144-0505-02 | 64144-0505 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | April 13, 2016 | In Use | |
65162-0805-14 | 65162-0805 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | April 3, 2015 | In Use |
Found 10,000 results in 9 milliseconds — Export these results